Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|May 19, 2026

The BioPharm Brief: Smarter Platforms, Safer Therapies, AI Acceleration

Today’s BioPharm Brief covers how biopharma companies are leveraging next-generation platform technologies—from CNS-targeted gene therapy and AI-driven R&D to antibody-cleaving biologics partnerships—to improve therapeutic precision, reduce development barriers, and expand access to advanced medicines.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today’s stories highlight a common trend emerging across the sector: companies are increasingly investing in platform technologies designed to make therapies more targeted, scalable, and efficient—from gene therapy delivery systems to artificial intelligence-enabled drug discovery tools.

First, JCR Pharmaceuticals presented new preclinical data at ASGCT 2026 supporting its JUST-AAV gene therapy platform, which is designed to improve delivery of therapies to the central nervous system while reducing unwanted liver exposure. The company reported encouraging findings in mouse models of neurodegenerative disorders including GM1 gangliosidosis and neuronal ceroid lipofuscinosis. Researchers observed improved CNS penetration, reduced neuroinflammation, and extended survival in treated animals. JCR says the platform could help address long-standing safety and delivery challenges associated with conventional AAV gene therapies.

Meanwhile, Hansa Biopharma announced an agreement worth up to $115 million with SERB Pharmaceuticals focused on expanding access to imlifidase, the company’s antibody-cleaving enzyme therapy. The deal centers on rare autoimmune and transplant-related conditions where pathogenic antibodies remain a significant barrier to treatment. The collaboration reflects continued interest in highly targeted biologic approaches capable of enabling transplantation and improving outcomes in difficult-to-treat patient populations.

And finally, Incyte and Edison Scientific unveiled a strategic collaboration aimed at integrating artificial intelligence across drug discovery and translational research workflows. Edison’s Kosmos AI platform will be embedded into Incyte’s R&D infrastructure to support target identification, biomarker analysis, and clinical data interpretation. The companies say the goal is to create a continuously learning system capable of improving research decisions over time by leveraging proprietary experimental and clinical datasets.

Taken together, today’s stories underscore how biopharma companies are increasingly pairing advanced biology with smarter enabling technologies to improve therapeutic precision, reduce toxicity risks, and accelerate development timelines.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights


• JCR Pharmaceuticals presented preclinical ASGCT 2026 data supporting CNS-targeted JUST-AAV gene therapy delivery with reduced liver exposure.

• Hansa Biopharma and SERB entered a licensing agreement focused on expanding access to imlifidase for transplant and autoimmune applications.

• Incyte partnered with Edison Scientific to integrate AI-driven predictive modeling across translational research and drug discovery workflows.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more